Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ketoprofen
Drug ID BADD_D01231
Description Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.
Indications and Usage For symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain.
Marketing Status approved; vet_approved
ATC Code M01AE03; M02AA10
DrugBank ID DB01009
KEGG ID D00132
MeSH ID D007660
PubChem ID 3825
TTD Drug ID D0W9WF
NDC Product Code 51604-0011; 71574-122; 0276-0506; 43235-0010; 51927-0304; 76465-0001; 12660-0006; 38779-3039; 49452-3924; 51927-0231; 45865-485; 0276-0504; 51927-0025; 51927-0057; 68981-031; 63275-9996; 82348-102; 63187-018; 38779-0078; 0378-8200; 51552-0307; 51927-0299; 79572-019
UNII 90Y4QC304K
Synonyms Ketoprofen | Benzoylhydratropic Acid | 2-(3-Benzoylphenyl)propionic Acid | Profenid | Alrheumum | Orudis | 19,583 RP | RP, 19,583 | RP-19583 | RP 19583 | RP19583 | Alrheumat
Chemical Information
Molecular Formula C16H14O3
CAS Registry Number 22071-15-4
SMILES CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
General physical health deterioration08.01.03.0180.003361%Not Available
Shock haemorrhagic24.06.02.014; 14.05.05.0030.003361%Not Available
Balance disorder08.01.03.081; 17.02.02.0070.002240%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Injection site swelling12.07.03.018; 08.02.03.0170.002240%Not Available
Vanishing bile duct syndrome09.02.03.0030.002240%Not Available
Rectal tenesmus15.05.03.011; 07.03.03.001--Not Available
Toxic skin eruption23.03.05.003; 10.01.01.008; 12.03.01.0730.002240%Not Available
Vasodilation procedure25.03.01.001--Not Available
Application site discolouration23.03.03.023; 12.07.01.030; 08.02.01.030--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.0270.002240%
Libido disorder21.03.02.006; 19.08.03.004--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Disease recurrence08.01.03.0500.002240%Not Available
Occult blood13.05.02.003--Not Available
Urinary tract pain20.02.03.013--
Renal impairment20.01.03.010--Not Available
Erosive oesophagitis07.04.05.0040.002240%Not Available
Liver injury12.01.17.012; 09.01.07.0220.006721%Not Available
Hypertransaminasaemia09.01.02.0050.004481%Not Available
Anorectal discomfort07.03.03.003--Not Available
Intestinal steatosis14.08.04.016; 07.11.01.011--Not Available
Kounis syndrome24.04.04.020; 02.02.02.020; 10.01.03.0370.003361%Not Available
Acute kidney injury20.01.03.0160.026884%
Drug-induced liver injury12.03.01.044; 09.01.07.0230.005601%Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 10.01.01.021; 12.03.01.0640.006721%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.002240%
The 9th Page    First    Pre   9 10    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene